Brimonidine Tartrate/Ketotifen Fumarate

酒石酸溴莫尼定/富马酸酮替芬

Report date: 2023/09/15 15:14:36
NME

Base Information

Drug NameBrimonidine Tartrate/Ketotifen Fumarate
Drug Alias NameBrimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdrenergic receptors alpha-2 agonistsHistamine H1 receptor antagonists
TargetsAdrenergic receptors alpha-2Histamine H1 receptor
Therapy Area/IndicationsConjunctivitis, Allergic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes Brimonidine TartrateKetotifen Fumarate
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBausch & Lomb Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesBausch & Lomb Incorporated
Inactive CompaniesN/A
Active IndicationsConjunctivitis, Allergic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A